Valeria Ferreira de Almeida e Borges

Dr. Valeria Ferreira de Almeida e Borges

Federal University of Bahia, Salvador, Bahia, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2012 in Journal of Clinical Ultrasound
Verified
Journal Article
Closed access
PDF file
Valeria Ferreira de Almeida e BorgesValeria Ferreira de Almeida e Borges
Valeria Ferreira de Almeida e Borges
VFValéria Ferreira
Valéria Ferreira
ADAngélica L. D. Diniz
Angélica L. D. Diniz
HCHelma P. Cotrim
Helma P. Cotrim
HRHaroldo L. O. G. Rocha
Haroldo L. O. G. Rocha
NANestor Barbosa Andrade
Nestor Barbosa Andrade

28 June 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
CACançado
Cançado
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado
MBMichelle Harriz Braga
Michelle Harriz Braga
MFMaria Lucia Gomes Ferraz
Maria Lucia Gomes Ferraz
CVCristiane Alves Villela-Nogueira
Cristiane Alves Villela-Nogueira
CCCláudia Alves Couto
Cláudia Alves Couto

1 January 2022 in Annals of Hepatology
Verified
Journal Article
Open access
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado
MBMichelle Harriz Braga
Michelle Harriz Braga
MFMaria Lúcia Gomes Ferraz
Maria Lúcia Gomes Ferraz
CVCristiane Alves Villela-Nogueira
Cristiane Alves Villela-Nogueira
DTDebora Raquel Benedita Terrabuio
Debora Raquel Benedita Terrabuio
CCCláudia Alves Couto
Cláudia Alves Couto
Little is known about primary biliary cholangitis (PBC) in non-whites. The purpose of this study was to evaluate clinical features and outcomes of PBC in a highly admixed population. The Brazilian Cholestasis Study Group multicentre database was reviewed to assess demographics, clinical features and treatment outcomes of Brazilian patients with PBC. 562 patients (95% females, mean age 51 ± 11 years) with PBC were included. Concurrent autoimmune diseases and overlap with autoimmune hepatitis (AIH) occurred, respectively, in 18.9% and 14%. After a mean follow-up was 6.2 ± 5.3 years, 32% had cirrhosis, 7% underwent liver transplantation and 3% died of liver-related causes. 96% were treated with ursodeoxycholic acid (UDCA) and 12% required add-on therapy with fibrates, either bezafibrate, fenofibrate or ciprofibrate. Response to UDCA and to UDCA/fibrates therapy varied from 39%-67% and 42-61%, respectively, according to different validated criteria. Advanced histological stages and non-adherence to treatment were associated with primary non-response to UDCA, while lower baseline alkaline phosphatase (ALP) and aspartate aminotransferase (AST) levels correlated with better responses to both UDCA and UDCA/fibrates. Clinical features of PBC in highly admixed Brazilians were similar to those reported in Caucasians and Asians, but with inferior rates of overlap syndrome with AIH. Response to UDCA was lower than expected and inversely associated with histological stage and baseline AST and ALP levels. Most of patients benefited from add-on fibrates, including ciprofibrate. A huge heterogeneity in response to UDCA therapy according to available international criteria was observed and reinforces the need of global standardization.

20 January 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado
CCCláudia Alves Couto
Cláudia Alves Couto
LGLaura Vilar Guedes
Laura Vilar Guedes
MBMichelle Harriz Braga
Michelle Harriz Braga
DTDébora Raquel Benedita Terrabuio
Débora Raquel Benedita Terrabuio
PBPaulo Lisboa Bittencourt
Paulo Lisboa Bittencourt
Aim: Up to 40% of patients with primary biliary cholangitis (PBC) will have a suboptimal biochemical response to ursodeoxycholic acid (UDCA), which can be improved by the addition of fibrates. This exploratory study aims to evaluate the long-term real-life biochemical response of different fibrates, including ciprofibrate, in subjects with UDCA-unresponsive PBC.Methods: The Brazilian Cholestasis Study Group multicenter database was reviewed to assess the response rates to UDCA plus fibrates in patients with UDCA-unresponsive PBC 1 and 2 years after treatment initiation by different validated criteria.Results: In total, 27 patients (100% women, mean age 48.9 ± 9.2 years) with PBC were included. Overall response rates to fibrates by each validated criterion varied from 39 to 60% and 39–76% at 12 and 24 months after treatment combination, respectively. Combination therapy resulted in a significant decrease in ALT and ALP only after 2 years, while GGT significantly improved in the first year of treatment. Treatment response rates at 1 and 2 years appear to be comparable between ciprofibrate and bezafibrate using all available criteria.Conclusion: Our findings endorse the efficacy of fibrate add-on treatment in PBC patients with suboptimal response to UDCA. Ciprofibrate appears to be at least as effective as bezafibrate and should be assessed in large clinical trials as a possibly new, cheaper, and promising option for treatment of UDCA-unresponsive PBC patients.

22 August 2022 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
CACançado
Cançado
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado
CCCláudia Alves Couto
Cláudia Alves Couto
DTDebora Raquel Benedita Terrabuio
Debora Raquel Benedita Terrabuio
EREduardo Luiz Rachid
Eduardo Luiz Rachid
PBPaulo Lisboa Bittencourt
Paulo Lisboa Bittencourt

1 January 2021 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
MNMateus Jorge Nardelli
Mateus Jorge Nardelli
PBPaulo Lisboa Bittencourt
Paulo Lisboa Bittencourt
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado
LFLuciana Costa Faria
Luciana Costa Faria
CVCristiane Alves Villela-Nogueira
Cristiane Alves Villela-Nogueira
CCClaudia Alves Couto
Claudia Alves Couto
Background. Primary sclerosing cholangitis (PSC) is associated with a broad phenotypic spectrum in different populations from diverse ethnic and racial backgrounds. This study aimed to describe the clinical characteristics and outcomes of PSC in a multicenter cohort of patients from Brazil. Methods. Data from the Brazilian Cholestasis Study Group were retrospectively reviewed to assess demographic information and clinical characteristics of PSC, as well as the outcomes, such as transplantation‐free survival. Results. This cohort included 210 patients. After excluding 33 (15.7%) patients with PSC and overlap syndrome of autoimmune hepatitis, 177 (97 males, median age 33 (21–42) years) with clear‐cut PSC were eligible for this study. Most of the patients (n = 139, 78.5%) were symptomatic, and 104 (58.7%) had advanced PSC at the time of diagnosis. Concurrent inflammatory bowel disease was observed in 78 (58.6%) of the investigated patients (n = 133), and most of them had ulcerative colitis (n = 61, 78.2%). The 1‐ and 5‐year survival free of liver transplantation or death were 92.3 ± 2.1% and 66.9 ± 4.2%, respectively, and baseline advanced PSC, pruritus, and elevated bilirubin levels were independent risk factors for the composite adverse outcome. Females were significantly older and had lower bilirubin levels than males at baseline, but survival was not associated with sex. Approximately 12.4% (n = 22) of patients with PSC died, and 32.8% (n = 58) underwent liver transplantation at a median follow‐up time of 5.3 and 3.2 years. Conclusion. Multiethnic Brazilian PSC patients exhibited a less pronounced male predominance and a lower frequency of inflammatory bowel disease than Caucasians. Adverse outcomes were more frequent, probably due to advanced disease at baseline.